Rachna Shroff/arizona.edu
Jul 5, 2025, 12:12
Rachna Shroff: Can We Expand How We Treat HCC?
Rachna Shroff, Associate Director Clinical Research at the University of Arizona Cancer Center, posted on X by European Society For Medical Oncology, adding:
“Can we expand how we treat HCC?
ESMOGI25 data suggests we can!
Key points:
– SIERRA: CP-B7/8, PS 2, or PVT tx’ed STRIDE safely → more patients may help, but results are promising
– ABSK-011-201: FGF19+ naive AND pre-treatment, impressive ORR, but mainly Hep B patients, uncertain applicability”
Quoting ESMO‘s post:
“ESMOGI25: New combinations show promise in HCC. Favourable responses were seen with irpagratinib plus atezolizumab in FGF19+ disease.
STRIDE had acceptable safety in poor-prognosis patients in the SIERRA Clinical Trial.
Read the ESMO Daily Reporter.”
More posts featuring Rachna Shroff on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 13:12
Jul 5, 2025, 13:07
Jul 5, 2025, 12:46
Jul 5, 2025, 12:24
Jul 5, 2025, 12:17